CurrentFidelis CarePolicy CP.FC.33

Clinical Policy: Autologous Hematopoietic Stem Cell Transplant (Pediatric)

Medical necessity criteria for autologous hematopoietic stem cell transplant in patients younger than 18 years, specifying covered disease indications, performance status, infection/substance use/social support requirements, and related coding guidance.

Policy Summary

PayerFidelis Care

PolicyClinical Policy: Autologous Hematopoietic Stem Cell Transplant (Pediatric)

Policy CodePolicy CP.FC.33

Change TypeAnnual reviewscoding and reference updatesadded caregiver requirement

Effective DateFeb 1, 2021

Next Review DateN/A

Key ActionProviders must document age (<18), disease-specific indication, performance status, therapeutic response, infection control, substance-use abstinence, and patient/caregiver understanding and social support for coverage determination.

SourceLink

POLICY UPDATE CHANGES

Added caregiver to medical necessity criteria: Patient understanding of procedural risk and post procedure compliance and follow-up.

Updated CPT codes and revised ICD-10 diagnosis codes in annual reviews (2023-2025).

References reviewed and updated annually (most recently 01/2025).

5Covered Indications (listed diseases A-E)

3Performance scales accepted

38206,38232,38241Key CPT codes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.